U.S. drugmaker Merck & Co. Inc. began recruiting participants to the company’s early-stage Covid-19 vaccine study, according to the government database clinicaltrials.gov.
Several Covid-19 vaccine developers, including Pfizer Inc., Johnson & Johnson and Moderna Inc., plan to issue a public pledge not to seek government approval until their vaccine candidates are proven to be safe and effective, the Wall Street Journal reported.
Johnson & Johnson aims to test the company’s experimental coronavirus vaccine in up to 60,000 volunteers in a late-stage trial scheduled to start in September, according to a U.S. government database of clinical trials.
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
BioNTech and Pfizer’s Covid-19 vaccine candidate is expected to be ready to seek regulatory approval by the end of 2020, the Wall Street Journal reported, citing the German biotech firm’s chief executive officer.
Companies Face Challenge of Enrolling Patients in COVID-19 Vaccine Studies Published: July 6, 2020 By Mark Terry BioSpace As of June 29, there were 13 vaccines against COVID-19 in human clinical trials. According to the World Health Organization, as of June 22, there were more than 140 vaccines in development. The furthest ahead are […]
Pfizer and Germany-based BioNTech, which are collaborating on a messenger RNA vaccine against SARS-CoV-2, plan to start testing in the United States once the Food and Drug Administration gives clearance.
As the world tries to limit the spread of the novel coronavirus that causes COVID-19, there is some hope that warmer weather will cause the virus to dwindle, like what happens with seasonal influenza. Though research indicates that COVID-19 could be seasonal, returning in the fall.
While employees of Cambridge, Massachusetts-based Biogen who attended a management meeting in Boston tested positive for COVID-19, numerous biopharma organizations are cancelling or postponing activities that involve large groups of people.
Japanese drug manufacturer Takeda Pharmaceutical indicated that the company is attempting to develop a drug based on the blood of patients who recovered from COVID-19.